{ "items": [ "\n\n
\n \n 28 May 2020\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Oxford University COSIE study (COvid-19, Social Isolation and Emotion) is an online study which asked people about their experiences during the coronavirus lockdown in late April 2020, while also using objective tests of psychological function to measure vulnerability to mental illness such as depression.
\n \n\n\n \n 28 May 2020\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nA new research survey launches today from experts at the University of Oxford along with collaborators from the Universities of Cambridge, Glasgow, and New South Wales. It will track adolescents\u2019 mental health during the COVID-19 crisis to find out what promotes or hinders their resilience.
\n \n\n\n \n 28 May 2020\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Nuffield Early Language Intervention catch-up programme developed by Maggie Snowling and Charles Hulme \u2013 has been found to give a 3+ month boost to the language skills of 4-5 year-olds who are falling behind.
\n \n\n\n \n 28 May 2020\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nKeeping grief hidden can be a survival strategy after suffering a bereavement. However, new research released today shows that the social disconnection caused by concealing feelings of loss can increase psychological distress.
\n \n\n\n \n 28 May 2020\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nNDCN researchers lead a global study based on analysing survey data
\n \n\n\n \n 28 May 2020\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nA team of NDCN neuroimaging researchers will lead this study, which has received a grant from the University of Oxford's COVID-19 Research Response Fund.
\n \n\n\n \n 24 April 2020\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nSupporting natural mood regulation is a new direct target for developing novel treatments, optimising existing ones and integrating drug and psychotherapies to reduce the disease burden of depression, according to new research, published in JAMA Psychiatry, from the Department of Psychiatry, University of Oxford.
\n \n\n\n \n 24 April 2020\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nResearch carried out by George Tofaris and his team has led to the development of a new way to test for Parkinson\u2019s disease before the main symptoms occur. This could allow clinicians to identify patients who would benefit from precision therapies that are currently at clinical trial stage.
\n \n\n\n \n 31 March 2020\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n \n \n Strategic Developments\n \n \n\n \n\n\n
\n \n\n \n \n \n \n \n\n\n \n 27 January 2020\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nA new review by researchers in the Department of Psychiatry of previous studies into suicide worldwide has highlighted the effects of individual and environmental risk factors over a lifetime.
\n \n\n\n \n 29 October 2019\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n \n \n Strategic Developments\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Oxford Epilepsy Research Group is at the forefront of some potentially ground-breaking work with patients who have drug-resistant epilepsy. Epilepsy affects over 50 million people worldwide and nearly one in three people with epilepsy are resistant to current drugs.
\n \n\n\n \n 29 October 2019\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Neurometrology Group has published findings from its OxQUIP study looking at how eye movements are affected by medication in Parkinson's.
\n \n\n\n \n 29 October 2019\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nOxford University researchers have discovered that learnt knowledge is stored in different brain circuits depending on how we acquire it.
\n \n\n\n \n 29 October 2019\n \n
\n\n \n\n \n\n \n \n \n \n Events\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nAt the five-year celebration event, scientists and health study volunteers from across the DPUK partnership came together to launch one of the world\u2019s most in-depth study's into preclinical Alzheimer\u2019s disease - one of the most important outcomes from DPUK's work to transform dementia research infrastructure in the UK.
\n \n\n\n \n 28 August 2019\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers from the Nuffield Dept of Clinical Neurosciences have found that a simple test carried out on a smartphone can help to predict future change in people in the early stages of Parkinson\u2019s.
\n \n\n\n \n 30 July 2019\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nPatients, carers and advocates say better evidence is needed on the safety of ketamine for depression after long-term use, and that those prescribed it must be closely monitored.
\n \n\n\n \n 30 July 2019\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \n \n \n\n\n \n 25 July 2019\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n \n \n Strategic Developments\n \n \n\n \n\n\n
\n \n\n \n \n \nThe delivery of clinical care, research, and education in neuro-rehabilitation in Oxford will be revolutionised by an innovative partnership with Quinnipiac University, Hartford, USA.
\n \n\n\n \n 27 June 2019\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n \n \n Strategic Developments\n \n \n\n \n\n\n
\n \n\n \n \n \nA new clinical trial is testing a virtual reality (VR) based psychological therapy for people with severe mental health difficulties. gameChange is the largest ever clinical trial of virtual reality for a mental health disorder. Automated delivery of therapy using VR has potential to transform NHS provision of psychological therapy.
\n \n\n\n \n 27 June 2019\n \n
\n\n \n\n \n\n \n \n \n \n Research Highlights\n \n \n\n \n\n\n
\n \n\n \n \n \nNew analysis shows the lower range of the licensed dose of the most commonly used second-generation antidepressants achieves the optimal balance between efficacy, tolerability and acceptability in the acute treatment of adults with major depression.
\n \n\n